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Defining the precise clean-up goals for lead (Pb) contaminated sites requires site-specific 42 
information on relative bioavailability data (RBA). While in vivo measurement is reliable 43 
but resource insensitive, in vitro approaches promise to provide high-throughput RBA 44 
predictions. One challenge on using in vitro bioaccessibility (BAc) to predict in vivo RBA 45 
is how to minimize the heterogeneities associated with in vivo-in vitro correlations 46 
(IVIVCs) stemming from various biomarkers (kidney, blood, liver, urinary and femur), in 47 
vitro approaches and studies. In this study, 252 paired RBA-BAc data were retrieved from 48 
9 publications, and then a Bayesian hierarchical model was implemented to address these 49 
random effects. A generic linear model (RBA (%) = (0.87 ± 0.16) × BAc + (4.70 ± 2.47)) of 50 
the IVIVCs was identified. While the differences of the IVIVCs amongst the in vitro 51 
approaches were significant, the differences amongst biomarkers were relatively small. The 52 
established IVIVCs were then applied to predict Pb RBA of which an overall Pb RBA 53 
estimation was 0.49 ± 0.25. In particular the RBA in the residential land was the highest 54 
(0.58 ± 0.19), followed by house dust (0.46 ± 0.20) and mining/smelting soils (0.45 ± 0.31). 55 
This is a new attempt to: firstly, use a meta-analysis to correlate Pb RBA and BAc; and 56 
secondly, estimate Pb RBA in relation to soil types.  57 
KEY WORDS：lead, bioavailability, bioaccessibility, meta-analysis, soil 58 
59 
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1. Introduction 60 
Lead (Pb) exposure in children is of worldwide concern, and soil and house dust have been 61 
considered a significant exposure pathway because Pb may be directly ingested and 62 
indirectly absorbed (Levin et al. 2008; Mielke and Reagan 1998). Incorporating Pb 63 
bioavailability, i.e. the fraction of an ingested dose that crosses the gastrointestinal 64 
epithelium and becomes available for distribution to internal tissues and organs, into human 65 
health and ecological risk assessment is increasingly acknowledged (Naidu et al. 2015; 66 
Ortega Calvo et al. 2015). The U.S. Environmental Protection Agency (EPA) suggests an 67 
overall relative bioavailability (RBA) in soil with reference to water and food is about 60% 68 
(U.S. EPA 2007). However, many studies have reported that Pb bioavailability varies 69 
extensively with the type of soils (Casteel et al. 2006; Li H et al. 2014; Li et al. 2015; 70 
Wijayawardena et al. 2015). For example, Li et al. (2015) and Li H et al. (2014) reported 71 
that Pb RBA ranged from 51% to 60% for farming soils, 31% to 84% for smelter soils, 7% 72 
to 26% for mining soils, and 29% to 60% for house dusts, respectively. Since Pb 73 
bioavailability may vary among soil types (Oliver et al. 1999; U.S. EPA 2007; 74 
Wijayawardena et al. 2015), it is necessary to use type-specific RBA to define the accurate 75 
clean-up goals for specific contaminated sites.  76 
 77 
In vivo and in vitro approaches, are commonly employed to estimate Pb RBA. Although in 78 
vivo measurements can directly provide reliable information on Pb RBA (Casteel et al. 79 
2006; Hettiarachchi et al. 2003), only limited information is available because it is 80 
time-consuming and expensive. Considering in vitro measurements are rapid, economical 81 
and reproducible, in vitro bioaccessibility (BAc) (Ruby et al. 1993) approaches promise to 82 
provide high-throughput RBA predictions if the correlation between in vivo RBA and in 83 
vitro BAc (IVIVC) can be validated. A challenge when using in vitro BAc to predict in 84 
vivo RBA is how to minimize the heterogeneities of IVIVCs. For example, five in vitro 85 
methods, namely the Relative Bioavailability Leaching Procedure (RBALP), unified 86 
BioAccessibility Research Group Europe (BARGE) method (UBM), Solubility 87 
Bioaccessibility Research Consortium assay (SBRC), Physiologically Based Extraction 88 
Test (PBET), and the In Vitro digestion model (RIVM), have been widely utilized for 89 
determining in vitro bioaccessibility (BAc) (Casteel et al. 2006; Dodd et al. 2013; Juhasz et 90 
al. 2009; Juhasz et al. 2013; Kesteren et al. 2014; Ruby et al. 1996). The IVIVCs based on 91 
each in vitro method have been previously reported (Casteel et al. 2006; Denys et al. 2007; 92 
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Denys et al. 2012; Deshommes et al. 2012; Kesteren et al. 2014; Li H et al. 2014; Schroder 93 
et al. 2004; Smith et al. 2011): results from U.S. EPA have documented that Pb RBA can 94 
be reliably estimated using RBALP assay and reported a regression equation 95 
(RBA=0.878×BAc-0.028) relating in vitro BAc to in vivo RBA (U.S. EPA 2007). Another 96 
study indicated experimental BAc based on SBRC is higher than the observed RBA when 97 
using rat model (Li H et al. 2014). A closer examination of these statistical relationships 98 
shows uncertainties do exist as exemplified by a fitted coefficient which has been reported 99 
as ranging widely from 0.39~1.87 (Deshommes et al. 2012).  100 
 101 
These uncertainties mostly stem from various in vitro measurements, different biomarkers, 102 
inter-laboratory variances, and model selections. For example, Yan et al. (2015) measured 103 
BAc on the same soils using different in vitro approaches. Further analysis showed that Pb 104 
BAc based on the RBALP and SRBC, RIVM models were comparable, while the slopes 105 
between RBALP and UBM can be up to 1.21 (Yan et al. 2015). Meanwhile, in vivo RBAs 106 
based on different biomarkers, including blood area under curve (AUC), liver, kidney and 107 
femur do not agree precisely with each other (Li H et al. 2014; U.S. EPA 2007). By 108 
integrating all the raw data, a meta-analysis promises to: firstly, determine the 109 
heterogeneities of IVIVCs, and secondly, to produce a comprehensive extrapolation 110 
(Axelrad et al. 2007; Whitehead 2002).  111 
 112 
In this study, paired BAc-RBA data, type-specific BAc and RBA data were retrieved from 113 
published reports. The objective of this study was to estimate Pb RBA with reference to 114 
soil types. This was achieved via two steps using: 1) meta-analysis to establish the IVIVCs 115 
and 2) established IVIVCs to predict RBA. The study presented here provides Pb 116 
site-specific RBA estimation to assist in Pb risk assessment and management. 117 
2. Materials and Methods  118 
2.1. Process for estimating site-specific Pb RBA.  119 
As shown in Figure 1, the procedure for estimating type-specific Pb RBA consisted of three 120 
steps. In the first step, three types of data (paired BAc-RBA, type-specific RBA, 121 
type-specific BAc) were collected. Using ‘lead’ & ‘bioavailability’ & ‘bioaccessibility’ as 122 
the keywords, an extensive literature search (for analyses published between 1950 and 123 
2015) was done and checked by the two co-authors (databases included Pubmed, Web of 124 
Science, Medline). The BAc-RBA paired data based on IVG and PBET were not 125 
considered in this study because no significant correlations were reported between such 126 
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two methods and other in vitro approaches (Yan et al. 2015). Meanwhile, the BAc data 127 
above 100% were omitted. Finally, the BAc measurements included four in vitro methods, 128 
RBALP, SBRC, UBM and RIVM. Two different solid: liquid ratio (1:37.5 and 1: 375) were 129 
used in the RIVM approaches. Five biomarkers, namely blood area under curve (AUC), 130 
liver, kidney, femur and urinary were also selected for indicating RBA. Since in vitro 131 
experimental parameters (pH, solid: liquid ratio and other factors) will influence the BAc 132 
measurements (Ryan et al. 2004), the procedures for each in vitro methods were identical in 133 
the pilot study (Yan et al. 2015). In the second step, the IVIVCs were developed by using a 134 
Bayesian hierarchical random-effects model and paired BAc-RBA data, and later the 135 
developed IVIVCs were used to convert type-specific BAc data into predicted RBA. In 136 
step 3, the RBA data, including the predicted RBA and reported RBA, was classified 137 
according to environmental media types. These media types were clustered into four 138 
categories: house dust, mining and smelting sites, residential land and others. The ‘others’ 139 
here included the soil samples from shooting range, incinerator, landfill, gasworks, etc. The 140 
BAc data were omitted when both the BAc and RBA data became available for the same 141 
soil samples. Table 1 summarizes the data collection, and all the raw data are available in 142 
Supplemental Material (SM) Tables S1, S2 and S3. It should be noted that some data in 143 
Table S1 and S3 were shared. 144 
 145 
2.2. Meta-analysis.  146 
When raw data are available a meta-analysis using a hierarchical approach is possible and 147 
this strategy can be used to address the effects from various factors (Whitehead 2002). In 148 
this study, a hierarchical random-effects model was employed, which is commonly utilized 149 
to combine relevant information from different studies (Axelrad et al. 2007). Here the 150 
heterogeneities were identified, consisting of three types, (i) individual effects, to represent 151 
the treatment differences from inter-lab, operations and other factors (ii) in vitro method 152 
effects and (iii) biomarker effects. This treatment can distinguish between heterogeneities 153 
to establish a ‘real’ link between the independent and dependent variables (Axelrad et al. 154 
2007).  155 
 156 
According to part 2 (meta-analysis) in Figure 1, the measured RBA (yij) was assumed to be 157 
of normal distribution with expected RBA (θij) and individual variance (sij2) (Whitehead 158 
2002): 159 
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2~ ( , )ij ij ijy N sθ                 (1) 160 
Here subscripts i and j represent different methods and endpoints, respectively. The 161 
variance of RBA has been observed to be a function of increasing RBA, which is referred 162 
to as heteroscedasticity (U.S. EPA 2007). To handle the heteroscedasticity, an option termed 163 
as an “external’’ variance, which is aimed to establish the relationship between variance 164 
and RBA has been recommended by U.S. EPA (2007) and adopted in this study. The 165 
detailed descriptions for variance estimation (sij2) are provided in the SM.  166 
 167 
Using expected RBA (θij) in Equation (1), the remaining heterogeneities can be described 168 
using Equations (2) and (3) 169 
2~ ( , )ij ijNθ µ δ                  (2) 170 
0 ( )ij ij i j ijx xµ β α γ λ= + × + + ×              (3) 171 
where the expected RBA (θij) was assumed to be the normal distribution with ‘real’ RBA 172 
(µij) and population variance 2δ , which accounts for the model residuals. A linear algorithm, 173 
as illustrated in Equation (3), has been applied to link the ‘real’ RBA (µij) and BAc (xij). β 174 
and α0 are the intercept and overall coefficient, respectively. (Yan et al. 2015). The 175 
remaining coefficients γ and λ account for the random effects from in vitro approaches and 176 
endpoints. Since data were collected based on different in vitro methods, BAc (xij) was 177 
firstly adjusted by using the established correlations among in vitro methods (SM Table S4) 178 
(Yan et al. 2015). Both the raw data and adjusted BAc data are provided in SM Table S1. 179 
Similarly, λ has been utilized to represent the endpoint random effects.  180 
 181 
The probabilistic and deterministic methods are both employed for mathematical modelling 182 
and parameter optimization. In this study all the objective parameters were fitted via 183 
Bayesian inference, a commonly used probability method. Compared to deterministic 184 
methods, the advantages of the Bayesian inference have been well summarized: interval 185 
estimation, the use of prior information and constraint test for parameters (Xu et al. 2006). 186 
All the procedures were simulated by matbugs, a Matlab (version 2012b) interface to 187 
WinBUGS that can execute Bayesian inference. Three Monte Carlo Markov Chains 188 
(MCMC) were simultaneously run until convergence was achieved. A Gibbs sampler was 189 
employed to obtain the parameters in each model. The pseudo-code for the simulation is 190 
provided in SM.  191 
 192 
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2.3. Model comparisons.  193 
The main objective of the curve-fitting is to find a mathematical model that fits the 194 
collected data reasonably well. However, the model itself neither has a mechanistic basis 195 
nor biological meaning. It is generally not appropriate to choose the form of the 196 
dose-response models based on only one function. In fact it is prudent to make the choice 197 
based on the weight of observations across many different regressions. Two alternative 198 
non-linear models (two parameters exponential, Equation (4); three parameters exponential, 199 
and Equation (5)) were also evaluated in this study (U.S. EPA 2007):  200 
0 exp( ) ( ) exp( )ij ij i j ijx xµ β α γ λ= + × + + ×            (4) 201 
0 exp( ) ( ) exp( )ij ij i j ijc x c xµ β α γ λ= + × × + + × ×           (5) 202 
 203 
2.4. Robustness analysis. 204 
A Jackknife resampling approach was employed to assess data bias in this study. The 205 
Jackknife estimator of a parameter is achieved by systematically leaving out each 206 
observation from a dataset and calculating the estimate, which is commonly used to 207 
estimate the bias and the standard error of statistics (Wu 1986). According to the various in 208 
vitro methods, studies and biomarkers, the raw data in SM Table S1 was classified into 29 209 
groups. With 1-deleted group in turn, the meta-analysis was re-run to obtain the objective 210 
parameters.  211 
 212 
2.5. Type-specific bioavailability estimations.  213 
The established IVIVCs were used to convert BAc data into RBA. Both the predicted RBA 214 
and collected RBA data (Figure 1, step 3) were applied to statistically summarize RBA 215 
according to its type.  216 
3. Results  217 
3.1. Data preparations and descriptions for meta-analysis.  218 
As summarized in Table 1, 252 paired RBA-BAc data points were collected from 9 219 
published reports. It is worth noting that the collected BAc data only included the data from 220 
gastric phase: the data from intestinal phase were excluded given the BAc under intestinal 221 
phase was always reported with BAc data for gastric phase for the same material. Including 222 
the BAc data from intestinal phase for the same material would outweigh this material’s 223 
impact. All the collected data are shown in Figure 2 and SM Figure S1.  224 
 225 
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The number of collected data based on RBALP (Bannon et al. 2009; U.S. EPA 2007) was 104 226 
(Table 1, Figure 2 legend cycle) and was the largest of all the methods considered for this 227 
study. Denys et al. (2012) have reported in vivo data and in vitro UBM data for 16 soils, 228 
however, the concentrations of 6 soils were beyond the linear range of the in vitro 229 
correlations (Yan et al. 2015). Consequently only 10 of the 16 soils have been included in this 230 
study, and the biomarker urine was only utilized in Denys et al. (2012). Some RBA data for 231 
the UBM (Wragg et al. 2011) and RIVM in vitro methods were derived from an in vivo study 232 
conducted by U.S. EPA (2007). 233 
 234 
The mean BAc in the in vitro methods varied as follows: SBRC (69%)> RIVM 235 
(62%-69%) >RBALP (64%) > UBM (37%). While the reported mean BAc based on UBM 236 
was significantly lower than the other three groups (Mann-Whitney test, p<0.001), no 237 
significant differences emerged among the other groups. While the ratio of RBA/BAc-RBALP 238 
and RBA/BAc-UBM was slightly higher than 1, the ratio of RBA/BAc-SBRC was approximately 239 
0.57 (Table 1).  240 
 241 
The raw RBA-BAc data used for meta-analysis have been presented in Figure 2. The size, 242 
color and style represent the variance, biomarker and in vitro method, respectively. It 243 
indicated that the size of the points with higher RBA was significantly larger than that with 244 
lower RBA, suggesting there may be a significant positive link between the variance and 245 
reported RBA. This linkage has been examined (Figures S2 and S3), and a function 246 
between variance (s2) and RBA (x) was done as follows: 247 
2( ) (1.65 0.33) ( ) (4.10 0.09)Ln s Ln x= ± × − ±          (6) 248 
This current study showed that the random effect of variance estimations using femur is 249 
slightly higher than for the other biomarkers. In particular, the random effects of variances 250 
from femur samples were positive (0.65). Conversely, blood AUC (-0.28), liver (-0.26), 251 
kidney (-0.17), and urine (0.0036) yielded negative random effects. The estimated variances 252 
were applied to Equation (1) for further meta-analysis.  253 
 254 
3.2. Meta-analysis, established IVIVCs and model comparisons.  255 
As stated above, the estimated variance (Equation (6)) alongside raw data were employed to 256 
help execute the hierarchical random effects model (Equations 1-3). The Gelman-Rubin (G-R) 257 
diagnostic method tested the convergence of the Monte Carlo sampling. By running three 258 
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parallel chains at any random start points, the results of the three MCMC chains should be 259 
similar. The idea of G-R test is that if the simulated MCMC has reached convergence, the 260 
within-run variation should be roughly equal to between-run variation (Xu et al. 2006).The 261 
simulation was considered to be converged when the Corrected Scale Reduction Factors (R) 262 
was < 1.20 (Xu et al. 2006). In this study, the reverse sampling simulations converged to R < 263 
1.10 for all population parameters.  264 
 265 
A random chain was chosen for shaping the population posterior distribution to obtain 266 
objective parameters in Equation 3, and therefore the IVIVC was developed as Equation (7). 267 
(%) (0.87 0.16) (4.70 2.47) ( , int)RBA BAc g method endpo BAc= ± × + ± + ×   (7) 268 
where function g represents the random effect from various methods and endpoints. As 269 
shown in Table 2 and Figure S4, the random effect for RIVM (1:37.5 Solid/Liquid ratio, 270 
termed as S/L ratio) was 0.32, which was the highest ratio. This was followed by RBALP 271 
(0.075), UBM (-0.018), and RIVM (1:375 S/L ratio) (-0.038) and SBRC (-0.37). Compared 272 
to the square of mean random effect for in vitro methods (0.25), this square of mean for 273 
biomarkers was much lower (0.0069). In particular, the random effects for liver was the 274 
highest (0.039), followed by blood AUC (0.018), urine (0.017), kidney (-0.018) and femur 275 
(-0.067).  276 
 277 
The Jackknife re-sampling approach was employed to address the data bias from each 278 
group. As a result, the means of re-simulated intercept and slope were estimated to be 4.77 279 
± 0.024 and 0.87 ± 0.0014, respectively (SM Figure S5). This low variation of coefficient 280 
(CV) for the intercept and slope (0.49% for intercept and 0.16% for slope) indicated all the 281 
groups may exert a limited influence on the model simulations.  282 
 283 
The alternative exponential models may potentially fit the dose response curve because 284 
Figure 2 suggested a higher slope for the higher RBA (the right side). Thus, two alternative 285 
non-linear models (Equations (4) and (5)) were also employed for model comparisons. As 286 
seen in Table S5, the two exponential models fit slightly better than the linear model (lower 287 
deviance information criterion). However, the improvement was below 1% and this was not 288 
enough to conclude that a non-linear fit is preferable to a linear model. Furthermore when 289 
using the power model to link RBA and BAc, the predicted RBA was not convergent when 290 
BAc was high. Considering the linear model has the most sophisticated theory and 291 
judgement system, the linear model was employed in the present study. As more data 292 
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become available in the future, the relationship between BAc and RBA will be reassessed 293 
and the model selection will be reviewed as necessary. 294 
 295 
3.3. Type-specific Pb bioavailability estimations. 296 
A total of 98 datasets for type-specific RBA and 105 datasets for type-specific BAc were 297 
retrieved (Table 1 and SM Table S2). In particular, 43, 3, 31 and 28 data were collected 298 
based on RBALP, RIVM, SBRC and UBM in vitro methods, respectively. RBA rank across 299 
four soil types differed from the rank concerning BAc. For example, the RBA for the 300 
residential land was the highest (62%), while the BAc for this type of soils (52%) was 301 
lower than house dust (57%).  302 
 303 
Using the established IVIVC and parameters in Table 2, the RBA for Pb was estimated 304 
according to different types of soils. No significant relationship (p=0.13) was observed for 305 
the Pb concentration (log-transformation) and RBA. The predicted RBA from BAc was 46 306 
± 18 %, while the published RBA was 52 ± 31%. Using the Mann-Whitney test, no 307 
significant difference (p=0.32) was found between the two types of RBA, which may 308 
confirm that the prediction based on BAc was comparable to the RBA based on in vivo 309 
studies. The boxplots for different soils across the data source are shown in Figure 3. An 310 
overall RBA was estimated to be 49 ± 25% (median: 47%), and the RBA for different types 311 
of soils are in the 45%-60% range. In particular, the RBA for the residential land was the 312 
highest (58 ± 19%, median: 58%), followed by house dust (46 ± 20%, median: 44%) and 313 
mining/smelting soils (45± 31%, median: 36%). The RBA for other soil types are 45 ± 24% 314 
(median: 45%). Meanwhile, the median RBA for the residential land, house dust, 315 
mining/smelting soils and other types were 58%, 44%, 36% and 45%, respectively. Various 316 
mining and smelting types may result in the high CV and differences between mean 317 
estimation (45%) and median estimation (36%) of the mining/smelting’s RBA. Significant 318 
differences were found between residential land and house dust (M-W U test, p<0.05), 319 
residential land and other soils (M-W U test, p<0.05). 320 
4. Discussion  321 
4.1. Implications of RBA-dependent variance.  322 
Usually, the ordinary linear squares regression (OLS) is employed to correlate RBA and BAc 323 
(Deshommes et al. 2012; Li H et al. 2014). With the OLS regression, the variances of the 324 
responses should be independent of the RBA (termed as homoscedasticity). However, 325 
Equation (6) indicated that this assumption is generally not satisfied, at least in this case. 326 
 12 
Casteel et al. (2006) have similarly estimated the link between RBA and variance. 327 
Furthermore the coefficient and intercept for different biomarkers have been reported with 328 
ranges of 1.55 to 2.10 and -2.60 to -1.32, respectively (Casteel et al. 2006), while the 95% 329 
confidential interval (CI) for the coefficient and intercept in our study were estimated to be 330 
0.96 to 2.30 and -4.29 to -3.92, respectively. The slope (1.65) we simulated here is within 331 
previous range, while the intercept (-4.10) was lower. However, the 95% CI for slope in this 332 
study (0.96 to 2.30) was wider than previous study and this may be due to heterogeneities 333 
from studies and biomarkers.  334 
 335 
Thus, considering the ‘RBA-dependent variances’, the weighted linear squares (WLS) 336 
regression has been recommended (Casteel et al. 2006; U.S. EPA 2007). In this study, 337 
according to the various studies and in vitro methods, we have clustered all data into 8 338 
groups (SM Table S6), and both the WLS and OLS have been applied to re-examine the 339 
data from each group to compare the two regressions. The mean RBA data for each group, 340 
i.e. the average bioavailability of the multiple biomarkers (if available) were applied, since 341 
differences among biomarkers were insignificant as demonstrated in this study. As shown 342 
in Table S6, 5 of the 8 functions were significant for the OLS and WLS approaches. The 343 
slopes were in the 0.61~1.08 range for OLS, while the values for WLS were all below 1. 344 
Particularly, in the estimate when using WLS, the highest coefficient was found for RBALP 345 
(0.84), followed by UBM (0.80), SBRC (0.44 - 0.78) and RIVM with 1:375 S/L ratio 346 
(0.70).  347 
 348 
It is noted that the coefficients based on the WLS were all below the values under OLS 349 
(paired t test, p=0.008). For example, the simulated coefficients decreased to 18%, 15%, 350 
16% and 26% for the raw data collected from U.S. EPA (2007), Li H et al. (2014), Denys et 351 
al. (2012) and Oomen et al. (2006), respectively. This may be explained by the difference in 352 
RBA/BAc slopes at the lower and higher BAc. As shown, the RBA/BAc slope when BAc 353 
is higher (>50%) (Figure 2) is steeper than the RBA/BAc slope when BAc is lower (<50%). 354 
Additionally, when the WLS was employed, this points to the BAc below 50% being 355 
weighted more than the BAc above 50% (since their variance was relatively low as stated 356 
in Equation (6)), which resulted in a lower simulated slope (relative to OLS)). However, to 357 
the best of our knowledge, there is no explicit explanation for the different slopes between 358 
the higher and lower RBA. This may be due to the fact that when BAc is higher, the in vitro 359 
methods are not able to extract the proportionate bioaccessible fraction. This has been 360 
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partly proven by the fact that the extraction abilities of the UBM and RIVM (1:37.5 S/L 361 
ratio) methods are limited when the bioaccessible fraction is high (Yan et al. 2015). 362 
Consequently, if extractability is limited when the bioaccessible fraction increases, the ratio 363 
between RBA and BAc may increase (as shown on right side of Figure 2). Therefore, our 364 
study suggests the IVIVCs using traditional OLS may need to be adjusted if the measured 365 
BAc crosses from a low value to a high BAc. 366 
 367 
While the OLS assumed the variance is independent, the WLS approach considers the 368 
magnitude of variance would increase with an increase in dose/response to overcome this 369 
‘heteroscedasticity’. A non-parametric method has been conducted in a previous study (Denys 370 
et al. 2012): this method used a repeated medians approach which specifically does not make 371 
any assumptions that the error is associated with the Y axis or that the residuals should be 372 
normally distributed. In this study, the strategy to treat the ‘heteroscedasticity’ is to use a 373 
normal distribution to account for variance. Meanwhile, the hierarchical model used in this 374 
study may be more informative, since it is also capable of separating the random effect from 375 
in vitro approaches and biomarkers (Equation 7 and Table 2). 376 
 377 
4.2. Comparisons of IVIVCs. 378 
Although previous in vivo RBA from different biomarkers results do not agree precisely 379 
(Casteel et al. 2006; U.S. EPA 2007) with each other, and we believe such differences are 380 
emerging from measurement and intra-species differences. Theoretically, using tissue 381 
concentration and blood concentration to estimate RBA and absolute bioavailability (ABA) 382 
should result in the same estimates. This study also demonstrated the differences among the 383 
biomarkers may be ignorable (Table 2), a finding that agrees with a recent study conducted 384 
on Arsenic (Li J et al. 2016).  385 
 386 
In this study, the generic coefficient for IVIVC was estimated to be 0.87 (95% CI: 0.55~1.19, 387 
Equation (7)). Although we have used the prior information to minimize the impact from in 388 
vitro methods (Table S4), the coefficient for RIVM (1:37.5 S/L ratio, 1.19), RBALP (0.95), 389 
UBM (0.85), RIVM (1:375 S/L ratio, 0.84) and SBRC (0.52) were considerably different. 390 
Denys et al. (2012) suggested the slope should be between 0.8 and 1.2. In this case, while the 391 
slopes based on RBALP (0.95), RIVM (1:37.5 S/L ratio, 1.19), UBM (0.85) and RIVM 392 
(1:375 S/L ratio, 0.84) were within this range, the only slopes based on SBRC (0.52) were 393 
slightly lower than the baselines. Surprisingly, previous studies indicated that the procedures 394 
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for RBALP and SBRC were identical (Yan et al. 2015), however, huge differences in the 395 
coefficient for RBALP (0.95) and SBRC (0.52) were observed in this study. The RBALP data 396 
largely derived from U.S. EPA (2007) yields a slope of 0.88 (Table 3), which is close to the 397 
estimation in the present study (0.95). Regarding another issue, most SBRC data originated 398 
from (Li H et al. 2014), and these two studies suggested low coefficient values (0.40 - 0.61, 399 
Table 3). This is a visual case explaining why it may be necessary to employ meta-analysis to 400 
consider research from inter-labs in order to achieve a reasonable result. The regression for 401 
SBRC and RBALP should not differ substantially from each other, while inter-study 402 
variances result in huge heterogeneities. More in vitro-in vivo experiments in the future may 403 
confirm that IVIVCs based on the two in vitro approaches do not differ, however, this 404 
judgement is not validated in current experiments.  405 
 406 
Previous IVIVCs based on the RBALP, UBM, SBRC and RIVM are summarized in Table 3. 407 
With the exception of Oomen et al. (2006), all the RBA/BAc slopes from other studies were 408 
below 1, which may indicate that per RBA change is more conservative than per BAc change. 409 
On another issues, the intercepts among the IVIVCs were reported as having a large range, 410 
from -0.028 to 30.21 (Table 3), while Denys et al. (2012) asserted the intercept should not be 411 
significantly different from 0. The difference between previous IVIVCs and developed 412 
IVIVCs in this study is we have integrated these reported IVIVCs to address the random 413 
effects. In this way, a less biased IVIVC is expected (Equation 7). It is in the meantime 414 
convenient to convert the BAc data into RBA data by choosing the appropriate parameters for 415 
the selected endpoints and in vitro approaches (Table 2). 416 
 417 
Some limitations have been acknowledged in establishing IVIVCs. For example, the sample 418 
size amongst the in vitro approaches differed. The sample size of the RBALP approach was 419 
104, while this value was only 12 for RIVM (1:37.5 S/L ratio). Such discrepancy would 420 
impact on the reliability and stability of the estimate for RIVM. Also, in this study, we did not 421 
consider the inter-species uncertainties of RBA. An underlying assumption here is the relative 422 
absorption ability among species should be the same. This assumption should be validated 423 
using various animals for the same soil, however, consistent data are presently not available. 424 
Another limitation here is that mining and smelting represent two different types of 425 
anthropogenic activities, causing different Pb speciation thereby variable Pb bioavailability in 426 
soil. However, since some previous studies mixed the two soil types, to compare between Pb 427 
bioavailability between mining and smelting impacted soils may require further investigation 428 
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in the future. Also, the variations of BAc were not considered in the analysis. For example, in 429 
some cases the CV of 46.8% was observed for Pb during inter-laboratory assessment of the 430 
UBM (Wragg et al. 2011). However, the variations of BAc are much lower than that of RBA 431 
as presented in SM Figure S1 in most cases. Thus, such a consideration may wield limited 432 
influence on the results. 433 
 434 
While these limitations may result in some error or bias in our study. a major aim of this 435 
study was to minimize reducible uncertainties when establishing IVIVCs. Based on all the 436 
available data and computational techniques, this study provides an informed attempt to 437 
better understand the relationships between RBA and BAc.  438 
 439 
4.3. Implications of RBA predictions. 440 
The RBA for residential land was observed to be higher than the other types. Of the collected 441 
data for residential land, the median Pb concentration was summarized as 1200 mg/kg. 442 
Therefore the daily soil intake for children can be up to 33.6 µg per day, based on IEUBK 443 
model simulation (model assumption: daily consumption for soil is 100mg) (U.S. EPA 2007). 444 
This value can increase to 3 to 6 µg/dL blood level for children aged 0.5 to 6, which 445 
contributes considerably when children are exposed to such levels of Pb.  446 
 447 
On the basis of type-specific RBA analysis conducted in this study, the soil types may not 448 
provide useful RBA predictions: only the differences between residential land and house 449 
dust, other soils were significant. However, an overall RBA estimation of 49 % in this 450 
study differed that from the RBA value of 60% that was selected by U.S. EPA in the 451 
IEUBK model (U.S. EPA 2002). This estimation indicated that the previous standard may 452 
be a conservative strategy. The lower estimate of RBA in this study may benefit the 453 
relevant stakeholder when establishing the clean-up goal and environmental regulations. 454 
For example, the IEUBK model helps the standard setting for soil (U.S. EPA 1998). 455 
Therefore a hazard standard of 400 mg/kg by weight in play areas and an average of 1200 456 
mg/kg in bare soil in the remainder of the yard were released (U.S. EPA 1998). If the lower 457 
RBA presented in this study can be updated in the IEUBK model, the outcome may be a 458 
more tolerable Pb exposure criterion. In reality, the site-types information may be unclear 459 
or contaminations may be from multiple sources. It is recommended that a prior assessment 460 
of site-specific BAc be undertaken, and then RBA can be predicted by applying the 461 
IVIVCs.  462 
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 463 
To the authors’ knowledge, this is the first time available data have been used to underpin 464 
IVIVCs analysis, and the robustness, reliability and comparisons of the established IVIVCs 465 
have been documented. Currently, developed IVIVCs still require future validation using in 466 
vivo experiments, and a validated IVIVC can be anticipated to help predict RBA, together 467 
with in vitro measurements. Meanwhile, RBA estimations presented here for different soil 468 
categories are simply empirical judgments. It should be noted that soils constitute variable 469 
material from site to site, and thus the RBA estimations should be treated with much caution 470 
in practice. In summary, this study is a new approach to estimating soil RBA according to soil 471 
types. Estimation of type-specific RBA can help: firstly, evaluate the potential risk arising 472 
from Pb exposure; and secondly, determine more precisely the clean-up goal. 473 
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Table 1. Summary of data collected from the literature 574 
Paired BAc-RBA data for IVIVC RBA (%) BAc(%) 
Methods Biomarker N Mean (Median) 
RBALP Blood/liver/kidney/femur 104 66 (70)  64 (71)  
SBRC Blood 29 40 (43) 69 (74) 
UBM Liver/kidney/femur/urine 67 49 (39) 37 (31) 
RIVMa Blood/liver/kidney/femur 40 52 (56) 62 (83) 
RIVMb Blood/liver/kidney/femur 12 72 (82) 69 (68) 
Type-specific BAc and RBA data  RBA (%) BAc(%) 
 Data typec N Mean (Median) 
House Dust Both 1 and 2 45 50 (52) 57 (66) 
Residential Both 1 and 2 59 62 (58) 52 (53) 
Mining/Smelter Both 1 and 2 77 50 (48) 40 (37) 
Others Both 1 and 2 22 38 (27) 68 (64) 
The raw data are available in Supplementary Materials Table S1, S2.  575 
 576 
Abbreviations. BAc: bioaccessibility; RBA: relative bioavailability; IVIVC: in vitro and in 577 
vivo correlation; RBALP: relative bioaccessibility leaching procedure; SBRC: 578 
Solubility/Bioavailability Research Consortium; UBM: BARGE Unified Bioaccessibility; 579 
RIVM: National Institute for Public Health and Environment method; N: sample number 580 
Note: a, S/L ratio is 1:375; b, S/L ratio is 1:37.5; c: 1 is type-specific BAc and 2 is 581 
type-specific RBA data.  582 
583 
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Table 2. Posterior estimations for model parameters, using Bayesian inference  584 
 585 
Parameter Mean (Median) SD 95% CI 
intercept (β) 4.70 (4.69) 2.47 (-0.13, 9.56) 
coefficient (α0) 0.87 (0.87) 0.16 (0.55, 1.19) 
study effect 
(γ) 
RBALP (γ1) 0.075 (0.075) 0.15 (-0.23, 0.39) 
SBRC (γ2) -0.37 (-0.36) 0.16 (-0.70, 0.056) 
UBM (γ3) -0.018 (-0.018) 0.15 (-0.33, 0.30) 
RIVMa (γ4) -0.038 (-0.037) 0.15 (-0.35, 0.28) 
RIVMb (γ5) 0.32 (0.32) 0.16 (-0.0088, 0.67) 
biomarker effect 
(λ) 
Blood (λ1) 0.018 (0.018) 0.055 (-0.086, 0.13) 
Liver (λ2) 0.039(0.037) 0.053 (-0.061, 0.13) 
Kidney (λ3) -0.018 (-0.015) 0.054 (-0.13, 0.079) 
Femur (λ4) -0.067 (-0.061) 0.057 (-0.19, 0.023) 
Urine (λ5) 0.017 (0.014) 0.066 (-0.11, 0.16) 
The parameter definitions are provided in Equation 3. 586 
   587 
Abbreviations. SD: standard deviation; CI: confidential interval; IVIVC: in vitro and in 588 
vivo correlation; RBALP: relative bioaccessibility leaching procedure; SBRC: 589 
Solubility/Bioavailability Research Consortium; UBM: BARGE Unified Bioaccessibility; 590 
RIVM: National Institute for Public Health and Environment method. 591 
Note: a, Solid/Liquid ratio is 1:375; b, Solid/Liquid ratio is 1:37.5. The parameters (β, α0, γ 592 
and λ) were defined in Equation 3.593 
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Table 3. Summary of reported IVIVCs 594 
Abbreviations. IVIVCs: in vitro and in vivo correlations; RBALP: relative bioaccessibility 595 
leaching procedure; SBRC: Solubility/Bioavailability Research Consortium; UBM: 596 
BARGE Unified Bioaccessibility; RIVM: National Institute for Public Health and 597 
Environment method. 598 
Note: a, Solid/Liquid ratio is 1:375; b, Solid/Liquid ratio is 1:37.5; c, based on weighted linear 599 
regression; d, x: bioaccessibility and y: bioavailability. 600 
Sample 
descriptions                  
(sample size) 





EPA region VIII 
(n=19) Swine/blood RBALP
c y = 0.88x - 0.028. r2 = 0.93 (U.S. EPA 2007) 
Soils                  
(n=12) Mice/blood RBALP  y = 0.69x + 30.21. r
2 = 0.78 (Smith et al. 2011) 
Farming, mining 
and smelter soils 
in China (n=12) 
Mice/blood SBRC y = 0.40x + 14.0. r2 = 0.43                        (Li et al. 2015)
House dust 
(n=24) Mice/blood SBRC y = 0.61x + 3.15. r
2 = 0.68                        (Li et al. 2014)
Farming, mining 
and smelter soils 
in China (n=12) 
Mice/blood UBM y = 0.80x + 9.99. r2 = 0.67                        (Li et al. 2015)
Mining and 





UBM y= (0.6 to 1.2)x+(0 to 5). r2 > 0.6                        (Denys et al. 2012)
Jasper Yard soils, 
residential soils, 
slag soils                   
(n=12)   
Swine/blood UBM  y = 0.78x, r2 = 0.61                          (Wragg et al. 2011) 
EPA Region VIII, 
Bunker hill 
(n=10)    
Swine/blood RIVM
a 
(0.06)  x = 1.08y, r
2 = 0.68                              (Oomen et al. 2006) 
EPA Region VIII, 
Bunker hill (n=7)    Swine/blood 
RIVMb 
(0.6)  x = 0.79y, r
2 = 0.95                           (Oomen et al. 2006) 
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Figure 1. Framework for estimating lead bioavailability. Model definition is provided in Equation 3. 607 
Abbreviations. BAc: Bioaccessibility; RBA: relative bioavailability; x: adjusted 608 
bioaccessibility; y: measured RBA; θ: expected RBA; µ: real RBA; s2: individual variance; 609 
σ2: population variance; β: intercept; α0: overall coefficient; γ: absolute coefficient 610 
differences among methods; λ: absolute coefficient differences among endpoints; IVIVC: 611 
















Figure 2. The scatter plot for bioaccessibility and relative bioavailability.  614 
Color: Blue (blood); Red (liver); Black (kidney); grey (femur); Green (urine).  615 
Method: circle (RBALP); Right-pointing triangle (SBRC); Left-pointing triangle (UBM); Upward-pointing 616 
triangle (RIVM,S/L ratio = 1:375); Downward-pointing triangle (RIVM,S/L ratio =1:37.5) 617 
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Figure 3. Boxplots for the type-specific Pb RBA  621 
 622 
For each box the central mark is the median, the edges of the box are the 25th and 75th 623 
percentiles, and the whiskers represent the most extreme data points without consideration 624 
of outliers.  625 
Abbreviations. BAc: Bioaccessibility; RBA: relative bioavailability; n, sample size.  626 
